|
2022–2026 |
Utilization of researh results in the Dermatology field |
|
2022–2025 |
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous
Pemphigoid |
|
2021–2023 |
A Randomized, Double-Blinded, Double-Dummy, Active-Comparator Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC Compared to Rituximab in Adult
Patients with Moderate to Severe Pemphigus (Vulgaris or Foliaceus) (ADDRESS)” ARGX-113-1904 |
|
2021–2023 |
An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of EfgartigimodPH20 SC in Patients With Pemphigus (ADDRESS+) ARGX-113-1905 |
|
2021–2029 |
Undergraduate Program Medical studies in English |
|
2020–2027 |
Stem cells and Regenerative Medicine |
|
2019–2022 |
Randomized double blind, placebo – controlled Multicenter trial to evaluate the efficacy and safety of oral BTK inhibitor PRN1008 in moderate to severe pemphigus |
|
2018–2024 |
Long term observational, prospective study to collect in a real life setting data on the retention, efectiveness, safety, treatment pattern, quality of life, and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis, psoriatic arthritis or ankylosis spndylitis. SERENA |
|
2016–2020 |
An open-label, phase 2, pilot, pilot study investigating the safety, clinical activity, pharmacokinetics, and pharmacodynamics of oral treatment with the BTK inhibitor ORN1008 in patients with newly diagnosed or relapsing pemhigus vulgaris |
|
2010–2014 |
Distinction funds from Aristotle University's Research Committee |
|
2009–2013 |
Real-word assessment of long-term infliximab therapy for psoriasis(Reality) |
